INmune Bio IncNASDAQ:INMB
- LAST PRICE4.8800
- TODAY'S CHANGE (%)0.0800 (1.6667%)
- Bid / Lots4.8500/ 5
- Ask / Lots5.2900/ 1
- Open / Previous Close4.8000 / 4.8000
- Day Range
- 52 Week Range
- Volume131,983
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INMB |
|---|---|---|
| 09:32 ET | 3201 | 4.82 |
| 09:33 ET | 2000 | 4.8957 |
| 09:35 ET | 200 | 4.825 |
| 09:39 ET | 800 | 4.74 |
| 09:44 ET | 1499 | 4.68 |
| 09:46 ET | 800 | 4.695 |
| 09:50 ET | 925 | 4.7195 |
| 09:55 ET | 637 | 4.72 |
| 10:04 ET | 100 | 4.75 |
| 10:15 ET | 300 | 4.76 |
| 10:18 ET | 200 | 4.75 |
| 10:22 ET | 1902 | 4.72 |
| 10:26 ET | 1509 | 4.7 |
| 10:36 ET | 400 | 4.715 |
| 10:38 ET | 298 | 4.725 |
| 10:42 ET | 929 | 4.7 |
| 10:51 ET | 100 | 4.725 |
| 10:58 ET | 1200 | 4.72 |
| 11:03 ET | 307 | 4.73 |
| 11:07 ET | 2123 | 4.73 |
| 11:12 ET | 395 | 4.73 |
| 11:14 ET | 200 | 4.7 |
| 11:16 ET | 100 | 4.69 |
| 11:18 ET | 100 | 4.71 |
| 11:23 ET | 6000 | 4.73 |
| 11:25 ET | 200 | 4.77 |
| 11:27 ET | 300 | 4.77 |
| 11:34 ET | 100 | 4.78 |
| 11:36 ET | 568 | 4.8 |
| 11:38 ET | 200 | 4.8 |
| 11:41 ET | 110 | 4.825 |
| 11:43 ET | 318 | 4.8224 |
| 11:54 ET | 456 | 4.84 |
| 11:56 ET | 500 | 4.84 |
| 12:03 ET | 900 | 4.83 |
| 12:10 ET | 200 | 4.825 |
| 12:12 ET | 974 | 4.8 |
| 12:15 ET | 500 | 4.8572 |
| 12:26 ET | 1400 | 4.89 |
| 12:28 ET | 500 | 4.9 |
| 12:48 ET | 1356 | 4.885 |
| 12:50 ET | 3395 | 4.86 |
| 12:51 ET | 200 | 4.84 |
| 12:55 ET | 727 | 4.86 |
| 12:57 ET | 300 | 4.88 |
| 01:04 ET | 200 | 4.8774 |
| 01:09 ET | 5141 | 4.855 |
| 01:24 ET | 100 | 4.84 |
| 01:26 ET | 200 | 4.82 |
| 01:38 ET | 800 | 4.81 |
| 01:45 ET | 300 | 4.835 |
| 01:47 ET | 133 | 4.83 |
| 02:03 ET | 600 | 4.85 |
| 02:07 ET | 400 | 4.8343 |
| 02:09 ET | 670 | 4.82 |
| 02:20 ET | 1800 | 4.86 |
| 02:21 ET | 300 | 4.84 |
| 02:36 ET | 100 | 4.84 |
| 02:41 ET | 1050 | 4.85 |
| 02:54 ET | 490 | 4.86 |
| 02:57 ET | 6300 | 4.86 |
| 03:01 ET | 350 | 4.865 |
| 03:08 ET | 300 | 4.88 |
| 03:10 ET | 200 | 4.86 |
| 03:12 ET | 300 | 4.87 |
| 03:21 ET | 880 | 4.86 |
| 03:24 ET | 100 | 4.86 |
| 03:28 ET | 112 | 4.87 |
| 03:32 ET | 1720 | 4.89 |
| 03:35 ET | 1327 | 4.89 |
| 03:37 ET | 4704 | 4.885 |
| 03:42 ET | 200 | 4.88 |
| 03:44 ET | 9000 | 4.8775 |
| 03:46 ET | 500 | 4.89 |
| 03:48 ET | 825 | 4.89 |
| 03:50 ET | 14539 | 4.9 |
| 03:51 ET | 804 | 4.885 |
| 03:53 ET | 200 | 4.88 |
| 03:55 ET | 500 | 4.875 |
| 03:57 ET | 969 | 4.87 |
| 04:00 ET | 7821 | 4.88 |
Nov 13, 2024
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease, from 9:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 31, 2024
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones*DJ INmune Bio 3Q Loss/Shr 60c >INMB, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 28, 2024
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB, from 8:00AM ET on Monday Oct 28, 2024 by Dow Jones
8:00AM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
INmune Bio Inc | 108.0M | -2.2x | --- |
Monopar Therapeutics Inc | 106.1M | -9.8x | --- |
Tiziana Life Sciences Ltd | 105.4M | -5.5x | --- |
CAMP4 Therapeutics Corp | 105.5M | -1.9x | --- |
Rani Therapeutics Holdings Inc | 111.5M | -1.8x | --- |
Context Therapeutics Inc | 104.2M | -1.6x | --- |
Company Information
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Contact Information
- Headquarters
- 225 Ne Mizner Blvd, Suite 640BOCA RATON, FL, United States 33432
- Phone
- 858-964-3720
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Raymond Tesi
- Chief Financial Officer
- David Moss
- Chief Scientific Officer
- Mark Lowdell
- Independent Director
- Marcia Allen
- Independent Director
- J. Kelly Ganjei
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $108.0M |
|---|---|
Revenue (TTM) | $42.0K |
Shares Outstanding | 22.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-2.18 |
Book Value | $2.12 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 2,570.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -98,921.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
